CANDONI, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 11.140
NA - Nord America 8.152
EU - Europa 4.663
SA - Sud America 1.312
AF - Africa 114
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 7
Totale 25.418
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.999
CN - Cina 4.816
SG - Singapore 2.929
HK - Hong Kong 1.602
IT - Italia 1.319
GB - Regno Unito 1.306
BR - Brasile 1.105
KR - Corea 669
RU - Federazione Russa 386
DE - Germania 338
SE - Svezia 337
VN - Vietnam 334
ID - Indonesia 218
FI - Finlandia 187
NL - Olanda 164
IN - India 151
LT - Lituania 127
UA - Ucraina 92
TR - Turchia 91
AR - Argentina 88
MX - Messico 73
JP - Giappone 70
FR - Francia 65
IE - Irlanda 65
AT - Austria 59
BD - Bangladesh 59
CA - Canada 52
IQ - Iraq 46
BG - Bulgaria 39
ZA - Sudafrica 34
ES - Italia 29
AU - Australia 28
EC - Ecuador 28
CO - Colombia 26
PL - Polonia 26
CZ - Repubblica Ceca 25
SA - Arabia Saudita 19
PK - Pakistan 18
MA - Marocco 17
EG - Egitto 16
PY - Paraguay 16
UZ - Uzbekistan 16
AE - Emirati Arabi Uniti 14
CH - Svizzera 13
CL - Cile 13
VE - Venezuela 13
KE - Kenya 12
TH - Thailandia 11
TW - Taiwan 11
UY - Uruguay 11
BE - Belgio 10
RO - Romania 10
GR - Grecia 9
HN - Honduras 9
HU - Ungheria 9
NP - Nepal 9
PT - Portogallo 9
IL - Israele 8
TN - Tunisia 8
AL - Albania 7
PE - Perù 7
BY - Bielorussia 6
DZ - Algeria 6
EU - Europa 6
HR - Croazia 6
JM - Giamaica 5
MY - Malesia 5
AZ - Azerbaigian 4
BO - Bolivia 4
KZ - Kazakistan 4
LV - Lettonia 4
OM - Oman 4
PS - Palestinian Territory 4
BA - Bosnia-Erzegovina 3
BB - Barbados 3
BN - Brunei Darussalam 3
CI - Costa d'Avorio 3
GE - Georgia 3
GT - Guatemala 3
IR - Iran 3
LY - Libia 3
MD - Moldavia 3
PH - Filippine 3
QA - Qatar 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
UG - Uganda 3
DO - Repubblica Dominicana 2
EE - Estonia 2
LB - Libano 2
LK - Sri Lanka 2
MW - Malawi 2
NO - Norvegia 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
BJ - Benin 1
Totale 25.398
Salva come PNG Salva come JPEG
Città #
Hefei 3.388
Singapore 1.938
Santa Clara 1.678
Hong Kong 1.525
Ashburn 826
London 690
Seoul 667
Fairfield 511
Southend 381
Houston 269
Woodbridge 260
Los Angeles 257
Seattle 219
Beijing 200
Kent 196
Chandler 195
Nyköping 191
Chicago 187
Jakarta 175
Wilmington 174
The Dalles 162
Ann Arbor 158
Cambridge 153
Buffalo 133
Jacksonville 130
Milan 123
New York 123
Dallas 121
Rome 121
Ho Chi Minh City 118
Dearborn 114
Moscow 114
Helsinki 113
Munich 106
São Paulo 103
Shanghai 86
Redondo Beach 81
Salt Lake City 79
Amsterdam 73
Hanoi 68
Dublin 65
Columbus 64
Modena 63
San Diego 61
Nuremberg 60
Bologna 57
Reggio Emilia 55
Delhi 48
Elk Grove Village 44
Tampa 43
Guangzhou 40
Princeton 40
Hillsboro 37
Mexico City 37
Sofia 37
Washington 37
Frankfurt am Main 36
Phoenix 36
Tokyo 36
Belo Horizonte 34
Brooklyn 34
Izmir 34
Boston 32
Rio de Janeiro 31
Kilburn 30
Eugene 29
Council Bluffs 27
Lappeenranta 25
Atlanta 24
Turku 24
Brasília 23
Sterling 23
Vienna 23
Warsaw 23
Boardman 22
Curitiba 22
Baghdad 21
Chiswick 21
Florence 21
Guarulhos 21
Porto Alegre 20
Hounslow 19
Des Moines 18
Melbourne 18
San Jose 18
Brno 17
Changsha 17
Lancaster 17
Montreal 17
Tianjin 17
Assago 16
Johannesburg 16
Stockholm 16
Turin 16
Verona 16
Naples 15
Campinas 14
Casale sul Sile 14
Detroit 14
Jersey City 14
Totale 17.975
Salva come PNG Salva come JPEG
Nome #
Characterization of Specific Immune Responses to Different Aspergillus Antigens during the Course of Invasive Aspergillosis in Hematologic Patients 364
A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients 306
Mucorales-specific T cells in patients with hematologic malignancies 285
Anagrelide in Essential Thrombocythemia: A Retrospective Analysis of 220 Patients. Session Type: Poster Session 646-III 266
All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. 257
Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study) 255
invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. 252
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial 228
Mucorles-specific T cells emerge in the course of invasive mucormucosis and may be used as a surrogate diagnostic marker in high-risk patients 221
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers 216
Peg Interferon alpha-2b (Peg Intron) in Essential Thrombocythemia 215
Identification and characterization of Aspergillus-specific immune responses to diagnose invasive aspergillosis in high risk patients: a multicenter study 214
PEG Intron in Essential Thrombocythemia: Two Years Treatment in 90 Patients. 208
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 206
Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: Feasibility and utility (SEIFEM-2008B study) 198
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. 193
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. 193
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) 190
Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use 188
Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data 187
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax 181
SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy 176
Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management 174
Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. 170
Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results. 165
Prognostic Relevance of Multi-Antigenic Myeloma-Specific T-Cell Assay in Patients with Monoclonal Gammopathies 163
PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study. 163
Bone marrow biopsy and aspirate evaluation in 90 patients with Essential Thrombocythemia treated with PEG interferon alpha-2b. Preliminary results 161
Distribution of different classes of CSF3R mutations and co-mutational pattern in 360 myeloid neoplasia 160
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 152
Early palliative care versus usual haematological care in multiple myeloma: retrospective cohort study 149
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 145
Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry 144
Severe acute respiratory syndrome coronavirus 2 infection in patients with hematological malignancies in the Omicron era: Respiratory failure, need for mechanical ventilation and mortality in seronegative and seropositive patients 142
Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation 142
COVID-19 omicron variant outbreak in a hematopoietic stem cell transplant unit 139
10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG 137
PEG Interferon a-2b (PEG-Intron) in Essential Thrombocythemia: Phase II Study for Determination of the Minimum Effective, Safe and Tolerated Dose. Preliminary Data. 136
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study 135
PEG Interferon alpha2b (PEG Intron) in Essential Thrombocytemia: Phase II Study for Determination of the Minimun Effective, Safe and Tolerated Dose. Preliminary Data. 135
Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GINEMA infection program 130
The Role of Wilms’ Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia 126
Advanced mast cell disease: An Italian Hematological Multicenter experience 125
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial 125
'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study 125
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 124
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM Experience 123
European Study of Cerebral Aspergillosis treated with Isavuconazole (ESCAI): A study by the ESCMID Fungal Infection Study Group 122
Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia 121
Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1mut) for the Treatment of NPM1mut-Acute Myeloid Leukemia 121
Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax 120
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study 116
Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial 114
Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience 113
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma 112
Intravascular lymphoma: Clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant' 112
Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin (NPM1) gene mutation subtypes: a single-center experience and review of the literature 112
Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia 112
Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy 111
Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE) 107
Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission 106
Acute myeloid leukemia in patients previously diagnosed with breast cancer: Experience of the GIMEMA group 105
Antibody Binding Capacity for Evaluation of MDR-Related Proteins in Acute Promyclocytic Leukemia: Onset Versus Relapse Expression 105
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 104
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 104
Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study 101
FLAI induction regimen in elderly patients with acute myeloid leukemia 100
Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes 99
Neurological complications in adult allogeneic hematopoietic stem cell transplant patients: Incidence, characteristics and long-term follow-up in a multicenter series 98
18F-FDG Positron Emission Tomography (PET) Scan as a Useful Tool to Assess Response to Antimycotic Therapy in Disseminated Invasive Mycosis in Acute Myeloid Leukemia 98
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO) 97
A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia 97
Up-front Blinatumomab Improves MRD Clearance and Outcome in Adult Ph− B-lineage ALL: the GIMEMA LAL2317 Phase 2 Study 96
Identification and validation of diagnostic cut-offs of the ELISpot assay for the diagnosis of invasive aspergillosis in high-risk patients 96
Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax 95
Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: An Italian multicentre prospective survey 95
Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey 94
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial 94
In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent 93
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph1 acute lymphoblastic leukemia 91
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice 90
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 90
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia 89
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol 89
Pneumocystis jirovecii pneumonia at chest High-resolution Computed Tomography (HRCT)in non-HIV immunocompromised patients: Spectrum of findings and mimickers 89
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission 88
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience 88
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 87
Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey 86
Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey 86
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial 85
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 85
Novel Gene Mutations Associated with Disease-Free Survival in Elderly Patients with Acute Myeloid Leukemia Receiving First-Line Induction-Consolidation with or without Azacitidine Post-Remission Treatment 84
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 84
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia 83
Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 82
Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study 82
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 82
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 81
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts 81
Totale 13.761
Salva come PNG Salva come JPEG
Categoria #
all - tutte 160.588
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 160.588
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021518 0 0 0 0 0 62 50 114 28 145 63 56
2021/2022729 38 101 59 44 30 57 34 42 87 52 90 95
2022/20231.245 79 47 43 53 88 87 319 130 200 28 72 99
2023/20242.253 58 67 144 201 370 187 325 230 54 65 223 329
2024/20259.165 218 117 96 624 1.549 1.063 390 347 1.016 886 1.539 1.320
2025/20269.658 1.801 1.492 2.461 2.005 1.240 659 0 0 0 0 0 0
Totale 25.792